Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung Clinical Trial

Official title:

Randomized Phase II Trial of Cyclophosphamide With Allogeneic Non-Small Cell Lung Cancer (NSCLC) DRibble Vaccine Alone or With Granulocyte-Macrophage Colony-Stimulating Factor or Imiquimod for Adjuvant Treatment of Definitively-Treated Stage IIIA or IIIB NSCLC

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01909752
• Other study ID #: UbiVac DPV-001
• Secondary ID: R44CA121612
• Status: Completed
• Phase: Phase 2
• First received: July 24, 2013
• Last updated: July 3, 2017
• Start date: July 2013
• Est. completion date: April 2017

Study information

• Verified date: July 2017
• Source: UbiVac
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will test an investigational vaccine, called DRibbles, for the treatment of non-small cell lung cancer (NSCLC). We hypothesize that vaccination with the DRibble vaccine will cause an immune responses against proteins contained in the DRibble vaccine and the protein antigens targeted by this strong immune response will include common antigens shared by both the vaccine and the patient's tumor.

Description:

This is an open-label, randomized study in which the first 33 patients will be assigned to receive the either:

• DRibbles vaccine and HPV vaccine

• DRibbles vaccine, HPV vaccine, and imiquimod

• DRibbles vaccine, HPV vaccine, and GM-CSF After 11 patients have been assigned to each group, the study arm with the greatest number of vaccine-induced strong antibody responses will then continue with enrollment of 15 further patients. The primary objective is to determine the best strategy to induce strong (>15 fold) tumor-specific or tumor-associated antibody responses in patients with stage III A and B NSCLC. The goal is to select one regimen to advance to additional clinical trials.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: April 2017
• Est. primary completion date: November 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Stage IIIA or IIIB histologically proven non-small cell lung cancer

• Completion of definitive therapy

• Enrollment from 28 days to 12 weeks from completion of definitive therapy

• Toxicities from definitive therapy resolved to less than grade 1

• ECOG performance status 0-1

• Negative pregnancy test in women of childbearing potential

• Agree to avoid pregnancy or fathering a child while on study treatment

• Ability to give informed consent and comply with protocol

• Anticipated survival minimum of 6 months

• Prior therapy with investigational agents must be completed at least 3 weeks prior to study enrollment

• Normal organ and marrow function as defined by specific lab tests

• Archived tumor tissue available

Exclusion Criteria:

• Active autoimmune disease except for vitilogo or hypothyroidism

• Active other malignancy

• Known HIV+ and/or Hepatitis B or C positive

• Medical or psychiatric conditions that would preclude safe participation

• Ongoing chemotherapy

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms

Intervention

Drug:
• Cyclophosphamide
Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy.

Biological:
• DRibble vaccine
DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43.

Drug:
• Imiquimod
Imiquimod cream (5%, 250 mg containing 12.5 mg imiquimod - one packet/day) will be self applied once per day starting with the second vaccine (week 4). Immediately following vaccination and for four days following each vaccine cycle (total 5 days) imiquimod will be applied to a 4 x 5-cm outlined area of healthy extremity skin that includes the vaccine site.
• GM-CSF
GM-CSF will be administered at 50 mcg/day starting with the second vaccine (week 4) and continuing with each subsequent vaccine. A volume of 0.2 cc will be delivered by the CADD-MSTM 3 Ambulatory infusion pump at a rate of 0.008 cc/hr. The pump will be refilled after three days for a total of six days of infusion.

Biological:
• HPV vaccine
Immunization with HPV vaccine will consist of two 0.5-mL intramuscular injection at the time of the first and third vaccinations. The preferred site of administration is the deltoid region of the upper arm.

Locations

Country	Name	City	State
United States	LSU Stanley S. Scott Cancer Center	New Orleans	Louisiana
United States	Providence Cancer Center	Portland	Oregon

Sponsors (6)

Lead Sponsor	Collaborator
UbiVac	Louisiana State University Health Sciences Center in New Orleans, Mayo Clinic, National Cancer Institute (NCI), Providence Cancer Center, Earle A. Chiles Research Institute, Providence Health & Services

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Identify the regimen that produces the strongest antibody response	The best regimen will be defined as the one that generates the greatest increase in the number of strong antibody responses as defined by a greater than 15-fold increase in antibody, as measured using the Immune Response Biomarker Profiling Array (Invitrogen) on the day 95 serum sample.	95 days
Secondary	Safety	To evaluate the overall safety of allogeneic NSCLC DRibble vaccine alone or in combination with either imiquimod or GM-CSF, as adjuvant treatment for definitively-treated patients with Stage IIIA or B NSCLC. During the treatment period, patients will be seen in clinic 13 times over a 22-week period; performance status and side-effects will be evaluated at each visit.	43 weeks
Secondary	Progression free survival	Evaluate progression-free survival. Tumor measurements by CT scan will be obtained at week 16 and subsequently at the discretion of the treating investigator. After the treatment period, patients will be seen every 3 months for 2 years, or until progressive disease.	2 years
Secondary	Immune response and progression-free survival correlation.	Evaluate whether any immune response data correlate with progression-free survival. Immune response data will be collected 12 times over the first 43 weeks and then every 3 months until two years or progressive disease. This data will be correlated with progression-free survival.	2 years